
GSK Q3 2018 results



All % at constant exchange rates (CER)

Sales grew across all three businesses



Herpes zoster

Adjusted Group operating margin

31.2%

+0.2%pts

Total EPS

28.8p

+23%

Adjusted EPS

35.5p

+14%

Year to date free cash flow

£2.4bn

Dividend declared for Q3 19p

See press release on www.gsk.com for full details on Q3 2018.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on page 38 of the press release.

CER% represents growth at constant exchange rates. For a full explanation please see page 37 of the press release.

